Eva Soler Espejo։ Atherogenic Index of Plasma and Residual Risk in Atrial Fibrillation
Eva Soler Espejo, Consultant Hematologist at Virgen de la Arrixaca University Clinical Hospital, shared a post on LinkedIn about a recent article she co-authored with her colleagues, adding:
”Anticoagulation in atrial fibrillation reduces risk — but does not eliminate it completely.
I am very pleased to share our latest publication in the Journal of the American Heart Association (JAHA).
In this prospective real-world study of anticoagulated patients with atrial fibrillation, we investigated whether the Atherogenic Index of Plasma (AIP) could help identify residual cardiovascular and thromboembolic risk.
Higher AIP levels were independently associated with worse clinical outcomes, particularly thromboembolic events and major adverse cardiovascular events (MACE), suggesting that this simple metabolic marker may provide incremental prognostic value beyond conventional risk assessment.
These findings underline the importance of better understanding residual risk in order to move towards more personalised and comprehensive management strategies in patients with AF.”
Title: Atherogenic Index of Plasma and Residual Risk in Anticoagulated Patients With Atrial Fibrillation: The Prospective Murcia Atrial Fibrillation Project III Cohort
Authors: Eva Soler‐Espejo, Yang Chen, José M. Rivera‐Caravaca, María P. Ramos‐Bratos, Francisco Marín, Vanessa Roldán, Gregory Y. H. Lip
Read the Full Article on Journal of the American Heart Association
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 20, 2026, 16:31Jerome Winegarden: ASH Continues to Show Exceptional Leadership by Advocating for Patients With Blood Diseases
-
Mar 20, 2026, 16:28Breanna Beers: A Remarkable Case of ‘Generation Skipping’ Marfan Syndrome
-
Mar 20, 2026, 16:26Results from The HUNT Study on The Role of Plasma miR-145-5p Levels in Cancer-Associated VTE – JTH
-
Mar 20, 2026, 16:22Welcoming Samer Al Hadidi to the Blood Cancers Team – UT Southwestern Simmons Cancer Center
-
Mar 20, 2026, 16:21Maxime Dely: The Lifesaving Power of Plasma Donations
-
Mar 20, 2026, 16:20Yves Bikorimana: Hemolysis – Why It Ruins Laboratory Results
-
Mar 20, 2026, 16:19Simon Senanu: G6PD Deficiency Testing – What the Lab Must Get Right
-
Mar 20, 2026, 16:18Khaled Elshazly: Can We Stop Chemotherapy-Induced Thrombocytopenia from Delaying Treatment?
-
Mar 20, 2026, 15:50Rithwic Mani: Platelet-to-Lymphocyte Ratio as A Simple and Cost-Effective Prognostic Biomarker in Stroke